Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab.
作者信息
Hertler Caroline, Seystahl Katharina, Le Rhun Emilie, Wirsching Hans-Georg, Roth Patrick, Weller Michael, Gramatzki Dorothee
机构信息
Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
Competence Center for Palliative Care, University Hospital Zurich, Zurich, Switzerland.
出版信息
Neuro Oncol. 2022 Nov 2;24(11):2001-2004. doi: 10.1093/neuonc/noac172.
Abstract
摘要
相似文献
1
Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab.贝伐单抗治疗复发性胶质母细胞瘤患者后癫痫控制情况改善。
Neuro Oncol. 2022 Nov 2;24(11):2001-2004. doi: 10.1093/neuonc/noac172.
2
Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors.接受血管紧张素系统抑制剂治疗的复发性胶质母细胞瘤患者使用贝伐单抗治疗的结果
Cancer Invest. 2018;36(9-10):512-519. doi: 10.1080/07357907.2018.1544639.
3
ADC quantification to classify patients candidate to receive bevacizumab treatment for recurrent glioblastoma.采用表观扩散系数（ADC）定量分析对复发性胶质母细胞瘤患者是否适合接受贝伐单抗治疗进行分类。
Acta Radiol. 2020 Mar;61(3):404-413. doi: 10.1177/0284185119864842. Epub 2019 Jul 29.
4
[Treatment of recurrent glioblastoma with single-agent bevacizumab].[单药贝伐单抗治疗复发性胶质母细胞瘤]
Orv Hetil. 2016 Mar 27;157(13):500-3. doi: 10.1556/650.2015.30395.
5
Bevacizumab in recurrent glioblastoma: five informative patient scenarios.贝伐单抗治疗复发性胶质母细胞瘤：五个典型病例分析
Can J Neurol Sci. 2015 May;42(3):149-56. doi: 10.1017/cjn.2015.21. Epub 2015 Apr 8.
6
Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma.闪回前言：贝伐单抗与伊立替康用于复发性胶质母细胞瘤
J Clin Oncol. 2023 Nov 10;41(32):4943-4944. doi: 10.1200/JCO.23.01865.
7
Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab.复发性胶质母细胞瘤患者贝伐单抗治疗的影像学和免疫化学参数与临床结局的相关性。
Clin Transl Oncol. 2019 Oct;21(10):1413-1423. doi: 10.1007/s12094-019-02070-6. Epub 2019 Mar 15.
8
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.复发性胶质母细胞瘤延迟使用贝伐单抗并不影响疗效。
Neuro Oncol. 2014 Oct;16(10):1427-8. doi: 10.1093/neuonc/nou214. Epub 2014 Aug 25.
9
MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.基于灌注 MRI 的贝伐珠单抗治疗复发性胶质母细胞瘤的血流动力学参数反应映射。
Radiology. 2016 May;279(2):542-52. doi: 10.1148/radiol.2015151172. Epub 2015 Nov 16.
10
Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?贝伐珠单抗治疗复发性胶质母细胞瘤患者：有效还是无效？
J Neurol. 2023 May;270(5):2702-2714. doi: 10.1007/s00415-023-11600-w. Epub 2023 Feb 22.
引用本文的文献
1
Seizure outcomes in patients with brain metastases and epilepsy: a systematic review on the efficacy of antitumor treatment and antiseizure medication.脑转移瘤和癫痫患者的癫痫发作结局：关于抗肿瘤治疗和抗癫痫药物疗效的系统评价
Neurooncol Pract. 2024 Oct 22;12(3):376-388. doi: 10.1093/nop/npae103. eCollection 2025 Jun.
2
AMPA Receptor Modulation in the Treatment of High-Grade Glioma: Translating Good Science into Better Outcomes.AMPA受体调节在高级别胶质瘤治疗中的应用：将优秀科学转化为更好的治疗结果
Pharmaceuticals (Basel). 2025 Mar 8;18(3):384. doi: 10.3390/ph18030384.
3
Patient-Centered Management of Brain Tumor-Related Epilepsy.脑肿瘤相关癫痫的以患者为中心的管理。
Curr Neurol Neurosci Rep. 2024 Sep;24(9):413-422. doi: 10.1007/s11910-024-01360-z. Epub 2024 Jul 17.
4
Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management.脑肿瘤相关癫痫的管理：神经肿瘤学会（SNO）对当前管理的共识综述。
Neuro Oncol. 2024 Jan 5;26(1):7-24. doi: 10.1093/neuonc/noad154.
5
Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial.基于癌症干细胞检测的化疗可改善复发性脑胶质瘤患者的生存预后：一项随机试验
Cell Rep Med. 2023 May 16;4(5):101025. doi: 10.1016/j.xcrm.2023.101025. Epub 2023 May 2.
6
Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management.蛋白激酶抑制剂作为免疫系统调节和脑癌管理的新靶点。
Int J Mol Sci. 2022 Dec 10;23(24):15693. doi: 10.3390/ijms232415693.
7
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours.2021 年版世界卫生组织中枢神经系统肿瘤分类的临床意义。
Nat Rev Neurol. 2022 Sep;18(9):515-529. doi: 10.1038/s41582-022-00679-w. Epub 2022 Jun 21.
本文引用的文献
1
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
2
Survival of brain tumour patients with epilepsy.脑肿瘤伴癫痫患者的生存情况。
Brain. 2021 Dec 16;144(11):3322-3327. doi: 10.1093/brain/awab188.
3
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients.替莫唑胺与老年胶质母细胞瘤患者随机临床试验中的癫痫发作结局。
J Neurooncol. 2020 Aug;149(1):65-71. doi: 10.1007/s11060-020-03573-x. Epub 2020 Jul 6.
4
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.成人脑胶质母细胞瘤：神经肿瘤学会（SNO）和欧洲神经肿瘤学会（EANO）关于当前管理和未来方向的共识综述。
Neuro Oncol. 2020 Aug 17;22(8):1073-1113. doi: 10.1093/neuonc/noaa106.
5
Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study.贝伐珠单抗可能改善胶质母细胞瘤患者的生活质量，但不能提高总体生存率：一项流行病学研究。
Ann Oncol. 2018 Jun 1;29(6):1431-1436. doi: 10.1093/annonc/mdy106.
6
Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review.低级别胶质瘤患者放化疗后的癫痫发作结局：一项系统评价
Neuro Oncol. 2015 Jul;17(7):924-34. doi: 10.1093/neuonc/nov032. Epub 2015 Mar 25.
Zotero 插件